HER2 copy number and resistance mechanisms in patients with HER2-positive advanced gastric cancer receiving initial trastuzumab-based therapy in JACOB trial.

Filippo Pietrantonio Francesco Pantano Sara Erika Bellomo Simona Corso Alessandra Raimondi Enrico Berrino Federica Morano Cristina Migliore Monica Niger Lorenzo Castagnoli Serenella Maria Pupa Caterina Marchio Maria Di Bartolomeo Eleonora Restuccia Chiara Lambertini Josep Tabernero Silvia Giordano

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

HER2 CNV-high assessed by NGS may be associated with better ORR, PFS, OS in a JACOB subgroup, especially if combined with HER2 3+. The negative prognostic role of AMNESIA requires further clinical validation.

Keyphrases

copy number
mitochondrial dna
phase iii
genome wide
dna methylation
clinical trial
study protocol
neoadjuvant chemotherapy
epidermal growth factor receptor
phase ii
open label
squamous cell carcinoma
gene expression
tyrosine kinase
rectal cancer